Àâòîðèçàöèÿ
Ïîèñê ïî óêàçàòåëÿì
Shepherd Ph.S. (ed.), Dean Ch. (ed.) — Monoclonal Antibodies: A Practical Approach
Îáñóäèòå êíèãó íà íàó÷íîì ôîðóìå Íàøëè îïå÷àòêó?
Íàçâàíèå: Monoclonal Antibodies: A Practical ApproachÀâòîðû: Shepherd Ph.S. (ed.), Dean Ch. (ed.) Àííîòàöèÿ: Monoclonal Antibodies: A Practical Approach covers the preparation, testing, derivation, and applications of monoclonal antibodies. New immunological techniques incorporating tried and tested methodologies are described, making the book of interest to established and inexperienced immunologists. Both the standard somatic hybridization technique and recombinant techniques, including the use of phage libraries, for the preparation of rodent and human monoclonal antibodies are described. Protocols for both the small and large scale production are detailed, as well as purification and labelling (with both radioisotopes and non-radioisotopes) methods. The applications of monoclonal antibodies in immunoblotting, enzyme linked immunoassays, immunofluorescence, and FACS analysis are all covered in detail. Finally protocols are given for the use of monoclonal antibodies in rheumatoid arthritis, tissue typing, detecting DNA modified during chemotherapy, and in the clinical analysis of transplantation samples for malignancy. This book will therefore be an invaluable laboratory companion to anyone using monoclonal antibodies in their research.
ßçûê: Ðóáðèêà: Ìåäèöèíà è çäðàâîîõðàíåíèå /Ñòàòóñ ïðåäìåòíîãî óêàçàòåëÿ: Ãîòîâ óêàçàòåëü ñ íîìåðàìè ñòðàíèö ed2k: ed2k stats Ãîä èçäàíèÿ: 2000Êîëè÷åñòâî ñòðàíèö: 479Äîáàâëåíà â êàòàëîã: 16.02.2007Îïåðàöèè: Ïîëîæèòü íà ïîëêó |
Ñêîïèðîâàòü ññûëêó äëÿ ôîðóìà | Ñêîïèðîâàòü ID
Ïðåäìåòíûé óêàçàòåëü
Murine mAbs, HAMA responses 451 Mycoplasmal contamination 126 Myeloma cell lines 3 Myeloma cell lines, choice 3—4 Myeloma cell lines, growth 6 9 Myeloma cell lines, preparation for fusion 10—11 N-hydroxysuccinimide ester coupling, immunoaffinity chromatography 324 Neomycin phosphotransferase II (npt-II) 187 Nickel-chelate chromatography 88 Nitrocellulose membranes electrotransfer 275-276 Non-denaturing PAGE 287—289 Non-equilibrium pH gradient, electrophoresis (NEPHGE) 283 286 Non-equilibrium pH gradient, stock solutions 285 Non-radioactive antibody probes 237—246 Nopaline synthase 187 Nunc cell factories 131 Octopine synthase 187 OKT3 438 Oligomeric complexes non-denaturing PAGE 287—289 Oligonucleotide primers for (ScFv) antibody library construction 33—34 Organ transplantation, animal models 435—436 Organ transplantation, mAb therapies 431—448 Organ transplantation, mAb therapies, choice 436—445 Ovines, myeloma cell lines 3 p-nitrophenol phosphate (PNPP) 86 Packed beds culture systems 140—142 PAGE 2D, polypeptides 283—286 PAGE non-denaturing 287—289 PAGE, analysis of antibody-antigen complexes 290 PAGE, SDS 270—273 Paraffin wax embedded tissues, fixation procedures 392—393 Paraformaldehyde, preparation 359 Particle bombardment-mediated gene transfer 192—196 Particle bombardment-mediated gene transfer, instrumentation 194—195 Particle bombardment-mediated gene transfer, principles 193—194 Particle bombardment-mediated gene transfer, transformation of wheat embryos 199—200 Particle bombardment-mediated gene transfer, vectors 195—196 PBMCs see “Peripheral blood mononuclear cells” PCR amplification, variable (V) region gene libraries 35—36 PCR, jumping-PCR assembly method 32 PCR, primary antibody genes 33—34 PCR, screening and fingerprinting 56—57 Peptides as immunogens 7 Peptides, conjugation to carriers 6 Peptides, conjugation to large proteins 7 Perfusion (high cell density) culture systems 137—143 Peripheral blood mononuclear cells preparation 114 Peripheral blood stem cell harvests, CD34 quantitation 378—379 Peripheral blood stem cell harvests, progenitor cell content analysis 377—382 Peripheral blood, fluorescence activated cell analysis (FACS) 371—389 Periplasmic extracts single chain Fv (ScFv) antibodies 87—88 Peroxidase mAb labelling 241 Peyer’s patches, immunization 7 Phage antibodies 25—57 Phage antibodies, PEG precipitation 68—69 Phage antibodies, selection from libraries of immunoglobulin genes 67 Phage display pHEN-1 vector ligation and insertion of scFv Ab 49—52 Phage display pHEN-1 vector purification by equilibrium centrifugation 46—49 Phage display pHEN-1 vector restriction digestion 49 Phage ELISA 83—84 Phage filamentous phage; antibody display and titration 69—70 Phage libraries 25—26 Phage libraries, electroporation-competent cells 52—54 Phage libraries, generation of human mAbs 451—452 Phage libraries, helper phage M13K07 72—73 84 Phage libraries, phagemids with immunoglobulin genes 67—89 Phage libraries, phagemids with immunoglobulin genes, storage and rescue 73 Phage libraries, preparation and storage 68—69 Phage libraries, selection by panning adherent cells 77—78 Phage libraries, selection cell surface selection 76—78 Phage libraries, selection cells in suspension 78 Phage libraries, selection on biotinylated antigen 74—76 Phage libraries, selection on purified immobilized antigen 71—74 Phage libraries, selection proximity selection 78—83 Phage libraries, selection screening of selected phage 83—87 Phage libraries, selection step back selections 83 Phage libraries, soluble scFv production and purification 87—88 pHEN-1 vector, ligation and insertion of scFv 49—52 pHEN-1 vector, purification 46 pHEN-1 vector, restriction digestion 49 Phosphate-buffered saline (PBS) 5 Phosphate-buffered saline (PBS), Dulbecco’s (D-PBS) 359 Phosphorus-32, radioimmunotherapy applications 230 Plants, mAb production 181—206 Plants, mAb production, advantages 202—203 Plants, mAb production, Agrobacterium tumefaciens-mediated transformation 188—192 Plants, mAb production, antibody fragments 182—183 Plants, mAb production, expression of recombinant proteins 181—186 Plants, mAb production, gene constructs 187—188 Plants, mAb production, hosts 182 Plants, mAb production, particle bombardment-mediated gene transfer 192—196 Plants, mAb production, plant transformation 186—202 Plasmid DNA 6 Plasmid DNA, preparation for particle bombardment 196 Plasmids, F conjugative plasmids 69—70 Poly(A+) mRNA, isolation 30—31 Polyacrylamide gel electrophoresis see “PAGE” Polyclonal antisera substitutes for mAbs 1 Polyethylene glycol solution 11 Polyethylene glycol solution, immunoassays 302 Polyethylene glycol solution, precipitation of phage antibodies 68—69 Polypeptides, 2D-PAGE 283—286 Polypeptides, SDS-PAGE 272—273 Polysome display 91—93 Ponceau S stain 275 276 Precipitation methods 156—58 Precipitation methods, PEG precipitation 68—69 Precipitation methods, salts 156—158 Pressure cooker high temperature antigen retrieval (HTAR) 397—398 Progesterone antibody DB3, model for ribosome display 105—106 Progressive lowering of temperature (PLT), EM immunocytochemistry 248—249 255—256 Protein A/G assays, affinity chromatography 158—162 Protein A/G assays, ELISA 175—176 Protein A/G assays, immunoaffinity chromatography 327—329 Protein characterization applications of mAbs 296 Protein purification technology 149—180 Protein purification technology, characterization of Ab 150 Protein purification technology, equipment 153—156 Protein purification technology, precipitation methods 156—158 Protein purification technology, problems 151—153 Protein purification technology, requirements, various applications 149—150 Protein separation, electrotransfer from gels to membranes 273—276 Protein separation, SDS-PAGE 270—273 Proteins, subcellular fractionation 287 Proteins, subcellular localization, immunofluorescence staining 287 Proteolysis, antigen retrieval 396-398 Proximity selection 78—83 Proximity selection, using guide antibody 80—81 Proximity selection, using natural ligands 81—83 Pyrimidines, BrdUrd flow cytometry 341—353 Quality control, fluorescence activated cell analysis (FACS) 376—377 Quality control, immunocytochemistry 407 Quality control, radiolabelling of mAbs 234—235 Rabbit, myeloma cell lines 3 Radioimmunoassays competitive 21 Radioimmunotherapy applications 229—231 Radiolabelling of mAbs 207—236 Radiolabelling of mAbs in vitro 207—217 Radiolabelling of mAbs in vivo 217—233 Radiolabelling of mAbs, fragments and constructs 234 Radiolabelling of mAbs, indirect/direct approaches 220 Radiolabelling of mAbs, measurement of immunoreactive fraction 214—215 Radiolabelling of mAbs, quality control 234—235 Radiolabelling of mAbs, ’Bolton and Hunter’ reagent 216 Radiolabelling, S-35 methionine 292—293 Radiolabelling, secondary Abs 277—278 Radionuclides, choice 208 Radionuclides, choice, radioimmunotherapy 230 Radionuclides, radiochemical purity by TLC 212—213 Rapid freezing methods 256—258 Recombinant antibodies 25—57 Recombinant antibodies, advantages 26 Recombinant antibodies, isolation of total mRNA from spleen 27—31 Recombinant antibodies, reverse transcriptase reaction 31—33 Recombinant proteins, expression in plants 181—186 Reporter molecules immunocytochemistry 402—405 Resin embedding, freeze-substitution 256—258 Resin embedding, progressive lowering of temperature (PLT) 248—249 255—256 Resin sections, EM immunocytochemistry, silver enhancement 258—261 Resin sections, light immunocytochemistry, silver enhancement 260 Restriction enzyme digestion pHEN-1 vector 49 Restriction enzyme digestion scFv DNA 44—46 Reverse transcriptase reaction recombinant antibodies 31—33 Reverse transcriptase-PCR 100—101 Rhenium, radioimmunotherapy applications 230 Rheumatoid arthritis, mAb therapies 449—461 Rheumatoid arthritis, mAb therapies, Campath-1 433 Rheumatoid arthritis, pathogenesis 449—451 Rheumatoid arthritis, therapies 450 Rheumatoid arthritis, therapies, mAbs 451—461 Ribosome display 91—93 (see also “ARM display”) RIPA buffer 266—268 292 Rodent monoclonal antibodies in vitro somatic hybridization 1—23 Rodent monoclonal antibodies, myeloma cell lines 3 Rodent monoclonal antibodies, myeloma cell lines, BALB/C strain 3 Rodent monoclonal antibodies, myeloma cell lines, LOU/wsl strain 3 Rodent monoclonal antibodies, peptide immunogens 2 Rodent monoclonal antibodies, spleen extraction 26—27 Roller bottle culture 135 Rosetting selection of antigen-specific B cells 116—117 RT, reverse transcriptase reaction 31—33 RT-PCR, DNA recovery, downstream primers, human, mouse 100—101 RT-PCR, vH/K recovery 101 S-35 radiolabelling methionine 292—293 Salt precipitation methods 144 156—158 Sandwich electrotransfer gels to membranes 273—276 Sandwich immunoassays 311—312 Scandium-47, radioimmunotherapy applications 230 ScFv see “Single chain Fvantibodies” Scintillation proximity immunoassays 303 Screening protocols 2 SDS-PAGE, polypeptides 272—273 SDS-PAGE, protein separation 270—273 SDS-PAGE, sample buffer 267 Secondary Abs, AP-conjugated 280 Secondary Abs, HRP-conjugated 280 Section adhesives 394 Section preparation 393—395 Section storage 394—395 Selenium, serum supplement 128 Separation techniques, equipment 153—156 Sequential determinants 2 Serum levels in culture 127 Serum levels in culture, cell adaptation to low levels 128—129 Serum replacements 128 Serum supplements 128 SfiI, and NotI, restriction enzymes, digestion of scFv DNA 44—46 SH-bonds, immunoaffinity chromatography coupling 325—327 Silver enhancement, EM immunocytochemistry, resin sections 258—261 Silver enhancement, immunogold probes, light microscopy 247—263 Single chain Fv (ScFv) antibodies 25 Single chain Fv (ScFv) antibodies in plants 182—183 Single chain Fv (ScFv) antibodies, assembly of single chain Fv Ab fragments 41—42 Single chain Fv (ScFv) antibodies, assembly of VH and VK fragments 39—41 Single chain Fv (ScFv) antibodies, DNA preparation using CsCl banding 47—49 Single chain Fv (ScFv) antibodies, electroporation-competent E. coli TGI cells 52—53 Single chain Fv (ScFv) antibodies, electrotransformation and plating 54—55 Single chain Fv (ScFv) antibodies, jumping-PCR assembly method 32 39—41 Single chain Fv (ScFv) antibodies, library construction jumping-PCR assembly 32 Single chain Fv (ScFv) antibodies, linker DNA preparation 37—39 Single chain Fv (ScFv) antibodies, oligonucleotide primers 33—34 Single chain Fv (ScFv) antibodies, PCR screening and fingerprinting 56—57 Single chain Fv (ScFv) antibodies, periplasmic extracts 87—88 Single chain Fv (ScFv) antibodies, pHEN-1 ligation and scFv insertion 49—52 Single chain Fv (ScFv) antibodies, pHEN-1 vector preparation 46—49 Single chain Fv (ScFv) antibodies, preparation 31—32 Single chain Fv (ScFv) antibodies, reamplification of scFv DNA 43—44 Single chain Fv (ScFv) antibodies, restriction enzyme digestion of scFv DNA 44—46 Single chain Fv (ScFv) antibodies, soluble (scFv) ELISA 85—87 Single chain Fv (ScFv) antibodies, soluble (scFv) production and purification 87—88 Single chain Fv (ScFv) antibodies, vH/K construction, ARM display 93—96 (see also “Antibody fragments”) Siran fixed porous bead reactors 141—142 Size exclusion chromatography 168—169 Small-scale production of mAbs 125—147 Sodium azide-phosphate-buffered saline (PBSA) 14 Somatic hybridization see “In vitrosomatic hybridization” Spinner flasks 131—132 Spleen, extraction technique 26—27 Spleen, generation of immune cells 7 Spleen, isolation of total mRNA 27—29 Stationary cultures, culture plates and flasks 129—130 Stationary cultures, monolayers 130 Stationary cultures, scale-up systems 130—131 STE solution 47 Stirred cultures 131—135 Stirred cultures, bioreactors 134—135 Storage of cells, cryopreservation 18—19 Storage of mAbs 173—174 Storage of mAbs, cryopreservation 122—123 Streptavidin-biotin complex detection 398—400 Streptavidin-coupled magnetic beads 98—99 Streptavidin-HRP 82 Subcellular localization of proteins, immunofluorescence staining 287 SuperSpinner flasks 133—134 Suppliers, addresses 463—468 T lymphocytes, analysis after transplantation or autologous rescue 384 T lymphocytes, animal models of transplantation and mAb therapy 435—436 T lymphocytes, depleting anti-T cell mAbs in RA 455—457 T lymphocytes, depletion 444—445 T lymphocytes, depletion, bone marrow 383—384 T lymphocytes, mononuclear cell fraction (MNC), cytokines 384—389 T lymphocytes, non-depleting anti-T cell mAbs 457—458 (see also “Campath-1H”) TAE buffer 28 TE buffer 28 Technetium-99m, characteristics and techniques 223—231 Technetium-99m, coordination cores 224 Technetium-99m, direct antibody labelling 225—227 Technetium-99m, indirect antibody labelling 227—231 Technetium-99m, pre-labelling 228—229 Technetium-99m, targeted radioimmunotherapy 229—230 Tecnomouse 138—139 Tetramethylrhodamine-5-isothiocyanate (TRITC) labelling 357 Thawed cryosections, methods for EM immunogold probes 251—255 ThermoPol reaction buffer 35 Thyrotropin receptor as immunogen 4 Ti plasmid, T-DNA, agrobacterium-mediated transformation 184 188—189 Tissue substrates, immunocytochemical staining 391—392 Tobacco, agrobacterium tumefaciens-mediated transformation 188—192 Tobacco, antibody fragment production 182—183 Tobacco, culture medium 197—198 Transfer sandwich, electrotransfer from gels to membranes 273—276 Transferrin, serum supplement 128 Transgenic plants, regeneration and screening for Ig chain production 200—202 Transgenic plants, self- and cross-fertilization 202 Transplantation for cancer FACS analysis 371—389 Transplantation of organs mAb therapies 431—448 TRI reagent 27 28 Tuberculin-purified protein derivative (PPD) 6—7 Tumour necrosis factor, anti-TNFalpha mAbs 452—453 Tyramine biotinylated, preparation 406—407 Tyrosine, incorporation of iodine-125 307 Tyrosine, residues 213 Tyrosine, side chains, iodination 209 Variable (V) region gene libraries 25 Variable (V) region gene libraries, PCR amplification 35—36 Variable (V) regions, homology matching 58 VCAMs in RA 454 Vectors, particle bombardment-mediated gene transfer 195—196 Vernier zone, CDRs 64 Vernier zone, residues 64
Ðåêëàìà
|
|
Î ïðîåêòå